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Background: Many peripheral biomarkers, including low cholesterol and its fractions, have been
examined to identify suicidal behavior. Herein, we assessed serum lipid proﬁle and some proteins
putatively associated with suicidal behavior in subjects with mood disorder (bipolar disorder or major
depressive disorder) with a recent suicide attempt and with no lifetime history of suicide attempts.
Methods: Fifty subjects had presented an episode of attempted suicide during the last 15 days, and 36
subjects had no history of any suicide attempt. We measured total cholesterol, HDL, LDL and triglycerides
as well as serum leptin, brain-derived neurotrophic factor (BDNF), S100B and C-reactive protein (CRP).
Results: Individuals that had attempted suicide presented decreased body mass index (BMI) and waist
circumference. After adjusting for these confounders, we found that triglycerides were decreased in
attempted suicide subjects. We found no differences among total cholesterol, LDL, and HDL or leptin,
S100B, CRP and BDNF.
Limitations: This is a cross-sectional study, and we cannot therefore assess whether a decrease in
triglycerides caused a mood episode with suicidal ideation that led to a suicide attempt or if the presence
of a mood episode originated a loss of appetite and consequent loss of weight, therefore decreasing
triglyceride levels.
Conclusions: These results do not support the hypothesis that lower levels of cholesterol are associated
with suicidal behavior in a mood disorder sample. However, our data support the idea that adiposity is
differentiated in these patients (reduced BMI, waist circumference and serum triglycerides), which could
lead to an altered communication between the adipose tissue and brain.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Suicide is a public health problem of high complexity, annually
causing a premature loss of approximately one million lives world-
wide (Bertolote and Fleischmann, 2002; Pompili et al., 2013), and
generating a wave of psychic events in family, friends and society
that are often irreparable. Many studies have searched for and
proposed biological markers that might be linked to suicidal behavior
and could be used as an additional tool for prevention and ther-
apeutic actions (Arango et al., 2003; Asellus et al., 2010; De Luca et al.,
2005; Lee and Kim, 2011; Marcinko et al., 2008; Pandey, 2013). Many
peripheral markers have been investigated in persons vulnerable to
suicide, including low serum cholesterol and its fractions (Atmaca
et al., 2002; Chang et al., 2012; Coryell and Schlesser, 2007; Jee et al.,
2011; Jokinen et al., 2010; Lee and Kim, 2003; Olie et al., 2011;
Papadopoulou et al., 2013; Troisi, 2009). This is intriguing, consider-
ing that persons with mood disorders [particularly bipolar disorder
(BD)] have an increased prevalence of metabolic syndrome, which
includes obesity, increased waist circumference and hyperlipidemia
(Fagiolini et al., 2005; Nousen et al., 2014; Vancampfort et al., 2013).
However, the biochemical connection reported between obesity and
suicidal behavior (Dutton et al., 2013; Mukamal and Miller, 2009)
demands further characterization, not only with regard to the serum
lipid proﬁle, but in relation to proteins associated with adipose tissue,
such as leptin (Eikelis et al., 2006).
The link between low cholesterol and suicidal behavior is not clear,
but the association between cholesterol and mental illness has
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attracted the interest of researchers for over a century (Cruickshank
and Tisdall, 1916; Poynder and Russell, 1926; Weston, 1915). Two
meta-analyses summarize our current knowledge regarding choles-
terol and suicidal behavior. Firstly, longitudinal studies show that
individuals with lower cholesterol levels do have a slightly, but
statistically signiﬁcant, increased risk of completing suicide (Lester,
2002); secondly, cholesterol-lowering treatments, such as statins, have
not been shown to increase non-illness mortality (including accidents,
trauma and suicide) (Muldoon et al., 2001).
We analyzed the lipid proﬁles of subjects with mood disorders
[BD and major depressive disorder (MDD)] and with a recent
suicide attempt and in subjects with no lifetime history of suicide
attempt. We aimed to determine whether total cholesterol, its
fractions and triglycerides were decreased in subjects that had
attempted suicide, as well as to investigate serum levels of other
proteins putatively associated with suicidal behavior: leptin
(Atmaca et al., 2008), S100B protein (Falcone et al., 2010), brain-
derived neurotrophic factor (BDNF) (Pandey et al., 2010) and
C-reactive protein (CRP) (De Berardis et al., 2008).
2. Methods and materials
2.1. Subjects and measurement
Eighty-six subjects with mood disorders (BD and MDD),
according to DSM-IV criteria, were enrolled in the study upon
admission to the São José Clinic, an inpatient psychiatric unit in
Porto Alegre, Brazil, from April 2010 to December 2012. Of those,
50 had presented a suicide attempt during the last 15 days, and 36
had no lifetime history of suicide attempt. Suicide attempts were
considered as “situations in which a person performs a life-threa-
tening behavior with the intent of jeopardizing his or her life, or to
give the appearance of such intent” (Beck et al., 1973; Brundin
et al., 2007). All study participants underwent a general physical
examination that showed no evidence of ongoing infection.
Individuals on antibiotics and anti-inﬂammatory medications
were excluded from the study. Demographic data and somatic
diagnoses for the study participants are shown in Table 1. All
subjects were on psychiatric medication for their current mood
episode at the moment of sample collection. According to the
criteria of Traskman et al. (1981), suicide attempters were further
divided into two subgroups: 20 subjects with a violent attempt
(5 subjects with a knife wound, 1 subject jumping from a high
place, 1 with a ﬁrearm, 7 that had tried to hang themselves, and
6 that had thrown themselves in front of a vehicle in movement),
and 30 with a non-violent attempt (medication ingestion and/or a
superﬁcial wrist cut). This study was approved by our local Ethical
Review Board for human studies (UFRGS, 18153) in accordance
with the 1964 Declaration of Helsinki. All subjects provided their
written informed consent before being enrolled in this study.
2.2. Biochemical measurements
All subjects were fasted overnight. Venous blood samples were
drawn from the antecubital vein at 08:00 a.m. After whole blood
was obtained, the serum was separated by centrifugation at
3000 rpm for 15 min and was then aliquoted at 80 1C until
analyses to determine the serum levels of cholesterol and trigly-
cerides, as well as leptin, S100B protein, brain-derived neuro-
trophic factor (BDNF) and C-reactive protein (CRP).
Total cholesterol, HDL, LDL and triglyceride levels were deter-
mined by colorimetric assays using Labtest Diagnostica Kits, as
indicated by the manufacturer, and employing the Labmax 240s
equipment from Labtest Diagnóstica (Minas Gerais, Brazil). Serum
S100B was measured by sandwich ELISA, as described previously
(Leite et al., 2008). BDNF and leptin were measured by sandwich
ELISA kits from Millipore (MA, USA). CRP was measured by a high
sensitivity turbidimetric immunoassay kit from Biotécnica (Minas
Gerais, Brazil), using the Labmax 240s for absorbance reading
(Labtest Diagnostica, Minas Gerais, Brazil).
2.3. Statistical analysis
Statistical analyses were performed using SPSS 17.0 for Win-
dows. All continuous variables are presented as means7standard
deviation (SD) or medians and interquartile range, as appropriate.
Categorical variables are presented as the raw number and
percentage (%). χ2 and Fisher's test were used to evaluate associa-
tions between categorical variables, as appropriate. For the com-
parisons of continuous variables among groups, we employed the
independent t test for parametric variables, and the Mann–
Whitney test for non-parametric variables. For analyses of total
cholesterol, LDL, HDL, triglycerides, BDNF, and leptin we used the
analysis of covariance (ANCOVA). Length of illness and of current
episode, sex, use of anticonvulsants or selective serotonin reuptake
inhibitor (SSRI), body mass index (BMI), and waist circumference
were used as covariates. As leptin was a highly skewed variable,
we applied a logarithmic transformation in order to use para-
metric methods. S100 and CRP were highly skewed and not
suitable for mathematical transformations, and therefore we used
non-parametrical methods. Pearson's and Spearman's correlations
coefﬁcients were used to analyze the correlations between para-
metric and non-parametric continuous variables, respectively. We
also analyzed the effect of the presence of suicide attempt as a
moderator in the correlations. Two-tailed p values o0.05 were
considered to be statistically signiﬁcant.
3. Results
A total of 86 subjects with mood disorders were included in this
study. Fifty subjects had presented an episode of suicide attempt
during the last 15 days, and 36 subjects had no lifetime history of
suicide attempt. The characteristics of the sample are summarized in
Table 1. All subjects were on current psychiatric medication at the
time of the suicide attempt and at the time of blood withdrawal. The
frequencies of the types of psychiatric medication were similar
between both groups, except for the use of anticonvulsants and SSRI
antidepressants, which were higher in the subjects without any
suicide attempt. Subjects with a recent suicide attempt had de-
creased BMI and waist circumference, when compared to subjects
that had not attempted suicide. We identiﬁed the presence of T2DM
(Type 2 diabetes mellitus) and hypothyroidism in subjects without
any history of suicide attempt. After adjusting for length of illness
and of current episode, sex, use of anticonvulsants and SSRI, BMI, and
waist circumference, we found that triglycerides were decreased in
attempted suicide subjects when compared to subjects without any
suicide attempt (103.45731.72 vs. 144.15774.48, p¼0.001) (Fig. 1).
We found no differences among total cholesterol, LDL, and HDLbetw-
een subjects with and without any suicide attempt.
Moreover, there were no differences among BDNF, S100B, CRP,
and leptin between those attempted suicide and non-suicide
subjects (Table 2). In addition, we found no difference in total
cholesterol, LDL, HDL, triglycerides, BDNF, S100B, CRP, and leptin
when analyzing the suicide attempters, according to the violence
of the act (data not shown).
We found a positive correlation between leptin and length of
illness (r¼0.24, p¼0.03), leptin and waist circumference (r¼0.32,
p¼0.003), and between leptin and BMI (r¼0.48, p¼0.001). The
correlation between leptin and BMI is clearly observed in subjects
with and without suicide attempt (Fig. 2A). There were positive
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correlations between CRP and waist circumference (r0¼0.32,
p¼0.003), and CRP and BMI (r0¼0.38, p¼0.001). However, the
presence of a suicide attempt did not act as a moderator in these
correlations (Table 3). Moreover, we found no correlation between
S100B and BDNF with any clinical characteristic, including BMI and
length of illness.
With regard to the serum triglycerides (the parameter that
differed between subjects with and without a history of suicide
attempt) we found no correlations between triglycerides and BMI
(r¼0.12, p¼0.261), triglycerides and waist circumference (r¼0.17,
p¼0.098), or triglycerides and length of illness (r¼0.08, p¼0.454).
The lack of correlation between triglycerides and BMI, observed in
mood disorder subjects with and without a history of suicide, is
shown in Fig. 2B.
4. Discussion
In contrast to current hypothesizes reported in the literature,
we did not ﬁnd any relationship between low total cholesterol and
its fractions and suicidal behavior in patients with mood disorders.
However, this lack of relationship is in agreement with some other
studies in the literature (Almeida-Montes et al., 2000; Asellus
et al., 2010; Paplos et al., 2012; Park et al., 2013; Persons et al.,
2012) and our data are in accordance with two other independent
and contemporary studies in individuals with BD and MDD, where
no differences were found in serum cholesterol content (Baek et
al., 2014; D'Ambrosio et al., 2012). We did not ﬁnd any difference
in total cholesterol, HDL or LDL. Commonly, psychiatric patients,
particularly with BD and MDD, have elevated BMI and other
metabolic abnormalities, which contribute to metabolic syndrome
(Carpiniello et al., 2012; Fiedorowicz et al., 2008; Lopresti and
Drummond, 2013). Herein, we found some differences between
suicide attempters and non-attempters in the sample of mood
disorders studied, particularly with regard to BMI and waist
circumference, which were both reduced in suicide attempters.
In agreement with these body parameters, the suicide attempters
exhibited lower serum triglycerides. It is important to emphasize
that the difference found in serum triglycerides (and not in
cholesterol) in suicide attempters was adjusted for gender and
BMI, which is generally underestimated in other cross-sectional
studies of suicidality [see Zhang (2011)].
Three demographic data parameters deserve consideration in our
sample; gender, length of illness and current episode and current
medication. The gender difference regarding risk of suicide attempt
is well known. Worldwide the risk of attempted suicide is higher in
females (Borges et al., 2010; Rihmer et al., 2013). Accordingly, our
study included more females than males with a history of attempted
suicide. Furthermore, the average time between the onset of disease
and the current suicide attempt was 10 years. This period has been
considered to present a higher risk of suicide in patients with both
BD and MDD (Tondo et al., 2003; Tsai et al., 2002). The use of SSRI
and anticonvulsants was lower in suicide attempters. Atypical
antipsychotics and anticonvulsants (particularly valproate) contri-
bute to insulin resistance and obesity (Pylvanen et al., 2006; Verrotti
et al., 2009). Notably, we did not ﬁnd any differences in the use
of antipsychotic drugs between suicide attempters and non-
attempters. Triglyceride levels were decreased in subjects without
suicide attempt even after adjusting for the use of anticonvulsants
and SSRI. However, since ours is a cross-sectional study, we cannot
Table 1
Characteristics of subjects with and without a history of suicide attempt.
Characteristic With suicide attempt (n¼50) Without suicide attempt (n¼36) P value
Socio-demographics
Male/femalea 11/39 12/24 0.048n
Age, yearsb 27.83712.21 32.28713.91 0.120
Education level, yearsb 10.2773.15 12.1773.09 0.064
Psychiatric disorder
Pathologya
Bipolar disorder 37 29 0.323
Current mania 23 16 0.658
Current depression 14 13 0.658
Major depressive disorder 13 7 0.323
Presence of psychosisa 21 8 0.133
Length of illness, yearsc 10.0 (3.0–20.0) 18.0 (11.0–30.0) 0.032n
Length of current episode, daysc 25.0 (15.0–60.0) 60.0 (30.0–180.0) 0.046n
Family history of psychiatric disordera 31 33 0.780
Current psychiatric medicationa
Antidepressants
SSRI 7 14 0.020n
Others 14 13 0.680
Lithium 15 11 0.570
Anticonvulsants 21 29 0.021n
Antipsychotics
Typical 28 17 0.280
Atypical 27 21 0.475
Metabolic characteristics
BMIb 24.6174.77 28.1376.41 0.001n
Waist circumference (cm)b 81.1479.48 96.68717.17 0.049n
T2DMd 0 2 0.310
Hypothyroidismd 0 2 0.310
Abbreviations: SSRI, selective serotonin reuptake inhibitor; BMI, body-mass index; T2DM, Type 2 diabetes mellitus.
n Columns show means7standard deviation (SD) for all categories except male sex, presence of psychosis, pathology, current psychiatric medication, family history of
psychiatric disorder, and presence of T2DM or hypothyroidism, which are presented as raw data. Length of illness and current episode are shown as median and
interquartile range.
a Chi-square test.
b Independent t test.
c Mann–Whitney test.
d Fisher's exact test.
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rule out that the use of anticonvulsant drugs, which were more
prevalent in the non-attempter group, contributed to the discre-
pancy observed in BMI and serum triglyceride levels. In another
study regarding BD, decreased cholesterol and triglycerides were
observed in suicide attempters (Vuksan-Cusa et al., 2009). Interest-
ingly, in Vuksan-Cusa's study the sample was free of psychotropic
medication, reinforcing the idea that medication is not the sole
contributor to changes in lipid proﬁle.
It has been proposed that a decreased serotonergic activity could
result in a poorer inhibition of impulsivity and, consequently,
suicidal behavior (Arango et al., 2002; Mann, 2013). In our study,
we observed that the prescription of SSRI in persons without suicide
attempts was higher than in those with suicide attempts. This
difference in prescribing may be secondary to a possible association
between the class of SSRI, particularly ﬂuoxetine, with violence and
suicide (Gunnell and Ashby, 2004; Hammad et al., 2006; Marcinko,
2007; Walsh and Dinan, 2001), although no consensus regarding the
direct relationship between antidepressant use and development of
suicidal ideation or behavior exists (Fazel et al., 2007; Hammad et al.,
2006; Miller et al., 2014; Walsh and Dinan, 2001). More recently, the
serotonergic system, widely established as being linked to suicidality
(Arango et al., 1995; Jokinen et al., 2009; Traskman et al., 1981), has
been studied in the area of genetics and presented interesting
results. For example, the presence of sequence variants in HTR5A
(serotonin type 5A receptor gene) was strongly associated with high
plasma levels of triglycerides (Zhang et al., 2010) and associations
between lower HDL cholesterol levels with depression were also
modiﬁed by a 5-HTTLPR (serotonin transporter gene linked promo-
ter region) polymorphism; however this association was only
signiﬁcant in the presence of one or more copies of the s (short)
allele (Kim et al., 2011).
Some studies have suggested that lower cholesterol can be
more linked to violent suicide attempts than suicidality itself [e.g.
(Atmaca et al., 2008)]. We did not ﬁnd a signiﬁcant difference in
Fig. 1. Fasting serum lipid proﬁle in subjects with and without a history of suicide attempt. (a) Total cholesterol, 181.00753.71 vs. 193.00744.70, respectively, p¼0.406. (b) LDL
cholesterol, 109.90744.97 vs. 111.55736.12, respectively, p¼0.504. (c) HDL cholesterol, 54.50718.54 vs. 55.39713.13, p¼0.810, and (d) Triglycerides, 103.45731.72 vs.
144.15774.48, p¼0.001. Data are shown as mean7standard deviation. Figure shows the mean and the 95% conﬁdence interval (CI) of the mean. Analysis of covariance
(ANCOVA) with length of illness and of current episode, sex, use of anticonvulsants and SSRI, BMI, and waist circumference as covariates.n denotes po0.05.
Table 2
BDNF, S100B, CRP, and leptin in subjects with and without a history of suicide
attempt.
With suicide attempt
(n¼50)
Without suicide attempt
(n¼36)
P
value
BDNF, pg/
mla
1070.947371.29 1045.387672.07 0.60
S100B, ng/
mlb
3.00 (1.00–7.00) 3.50 (1.00–7.75) 0.85
CRP, mg/lb 4.00 (1.00–9.00) 3.50 (2.00–6.00) 0.89
Leptin, ng/
mla,c
2.7471.12 3.0571.19 0.65
Abbreviations: BDNF, brain-derived neurotrophic factor; CRP, C-reactive protein.
a Independent t test, mean and standard deviation.
b Mann–Whitney test, median and interquartile range.
c Log-transformed variable.
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serum cholesterol between violent and non-violent attempters, in
agreement with a previous study in BD (D'Ambrosio et al., 2012).
We also did not ﬁnd any difference in triglyceride levels between
violent and non-violent suicide attempters.
This study also evaluated other markers related to adiposity,
namely leptin, CRP and S100B (Eikelis et al., 2006; Steiner et al.,
2010a). BDNF was also investigated because it is widely involved in
body energetic homeostasis and commonly associated with psy-
chiatric disorders with an elevated rate of suicide (Fernandes et al.,
2013, 2011; Marosi and Mattson, 2014).
Serum leptin, an adipocyte-derived protein regulator of food
intake, has a positive correlation with BMI [e.g. (McConway et al.,
2000)]. Leptin (together with cholesterol) was found to be reduced in
suicidal patients, compared to healthy controls (Atmaca et al., 2008,
2002). In addition, low levels of cerebrospinal leptin were found in
female suicide attempters with major depression (Westling et al.,
2004), in agreement with reduced levels of brain leptin observed in
suicide victims (Eikelis et al., 2006). However, serum leptin was not
altered in pregnant women with a higher suicide risk (Farias et al.,
2013). Herein, we found a positive correlation of leptin with BMI in
our sample, but no difference was found in serum leptin between
patients with and without a history of suicide. This ﬁnding contends
the idea that serum leptin may act as a suicidality marker in patients
with mood disorders. Moreover, we did not ﬁnd an association
between CRP and a history of suicide in patients with mood disorders.
However, the positive correlation between CRP and BMI and CRP and
waist circumference in these patients reinforces the idea that a
systemic inﬂammatory process (including adipose tissue) may con-
tribute to the pathophysiology of mood disorders (Kling et al., 2007).
No differences were observed in serum BDNF and S100B between
mood disorder subjects with and without a history of suicide.
Moreover, no correlation was found between these proteins and
the anthropomorphic signals of adiposity observed in these patients
(BMI or waist circumference) or these proteins and the length of
illness. Serum BDNF was reduced in suicidal individuals soon after
an attempted suicide (Dawood et al., 2007), in agreement with the
changes in brain BDNF and its receptors observed in postmortem
studies of depressive patients (Lee and Kim, 2011). Our sample
included patients with suicide attempts during the last 15 days, time
enough to “recover” possible decreases in the peripheral levels of
BDNF associated with a suicidal attempt. However, further studies
are necessary to clarify this question. S100B increments have been
reported in many conditions of brain injury and neurodegenerative
diseases (Kleindienst et al., 2007; Rothermundt et al., 2003). Serum
S100B protein comes from the brain and from other non-neural
sources, particularly adipose tissue (Goncalves et al., 2010, 2008). In
fact, serum S100B levels in humans appear to closely reﬂect adipose
tissue mass (Gross et al., 2010; Steiner et al., 2010a). Some studies
have shown elevated levels of serum S100B in episodes of mood
disorders, and these elevations were more evident in major depres-
sive disorder than in bipolar disorder (Schroeter and Steiner, 2009).
We found elevated levels of S100B (compared to those of healthy
individuals) [e.g. (Andreazza et al., 2007; Schroeter et al., 2011)], but
no difference was found between patients with and without a
Fig. 2. Correlations between leptin or triglycerides with body-mass index (BMI). A positive correlation between leptin and BMI is observed (in a, r¼0.48), but no correlation
between triglycerides and BMI (in b, r¼0.12). History of suicide attempt is not a moderator of the correlations (p40.05).
Table 3
Analysis of a “history of suicide attempt” as a moderator of the correlations
between body-mass index and length of illness in years with C-reactive protein,
leptin, brain-derived neuotrophic factor (BDNF), protein S100B, and lipidic proﬁle.
R values with suicide
attempt (n¼50)*
R values without suicide
attempt (n¼36)*
P
value
BMI vs. BDNF 0.17 0.15 0.472
BMI vs. CRP 0.38 0.45 0.563
BMI vs. Leptin 0.45 0.39 0.555
BMI vs. S100B 0.08 0.05 0.549
Length of
illness vs.
BDNF
0.26 0.06 0.289
Length of
illness vs.
CRP
0.01 0.15 0.782
Length of
illness vs.
Leptin
0.19 0.25 0.878
Length of
illness vs.
S100B
0.16 0.06 0.281
n Columns show Pearson's correlation (r). The P values refers to the effect of the
presence of suicide attempt as a moderator to the correlations.
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history of suicide attempt. Moreover, no correlation was found with
BMI. Interestingly, this lack of correlation was also observed in
schizophrenic patients and attributed to insulin resistance in these
patients (Steiner et al., 2010b). However, augmented S100B was
correlated with the severity of suicidal ideation in adolescents with
psychosis or mood disorders (Falcone et al., 2010). As such, this
matter demands further studies.
Our study presents some limitations; ﬁrstly, our sample is
probably underpowered to detect a difference in total cholesterol
between subjects with and without a history of suicide attempt.
However, in support of our analysis, another cross-sectional study
of a sample of schizophrenic patients, also adjusted for gender and
BMI, found no association between cholesterol and suicidal
behavior (Huang and Wu, 2000). Secondly, all subjects were on
medication and a higher number of non-suicidal persons were on
anticonvulsants, drugs known to increase insulin resistance;
however, we adjusted for this type of medication in our analysis.
Thirdly, ours was a cross-sectional study, and we cannot therefore
assess whether a decrease in triglycerides caused a mood episode
with suicidal ideation that led to a suicide attempt or if the
presence of a mood episode originated a loss of appetite and
consequent loss of weight, therefore decreasing triglyceride levels.
Taken together our data suggest that suicide attempters with
mood disorders exhibit less adiposity, expressed as a reduced BMI,
waist circumference and serum triglycerides, when compared to
non-attempters. Our data opposed the idea that serum leptin, CRP
and S100B could represent the markers of suicidality in patient
with mood disorders. However, further studies are investigating
these and other markers related to adiposity, such as ghrelin
(Atmaca et al., 2006), are necessary not only to diagnose such
behavior, but for the follow-up of treatment of psychiatric diseases
with elevated rates of suicide.
5. Conclusions
We did not ﬁnd any decrease in serum cholesterol when
comparing suicide attempters with non-attempters in a sample
of subjects with mood disorders. However, we found a reduced
adiposity in suicide attempters, as indicated by reduced BMI, waist
circumference, and peripheral triglycerides. These data do not
support the hypothesis that lower levels of cholesterol are asso-
ciated with suicidal behavior. Moreover, although peripheral levels
of leptin, BDNF, S100B and CRP may be associated with mood
disorders, we did not ﬁnd any difference in the levels of these
proteins in subjects that had a history of suicide, or not. However,
our data contribute to the idea that adiposity is differentiated in
these patients, which could lead to an altered adipose tissue–brain
communication.
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